In a recent article from Managing IP on the increase in demand for financing in life sciences IP, Director Anup Misra discussed that he is seeing more requests for funding in that sector than in previous years.
According to Misra, “More life sciences companies are beginning to look at funding as an avenue to enforce their IP. It’s a lot more mainstream. More law firms are educated about it and it’s in the press.”
Misra went on to add that life science companies that have broader portfolios are beginning to seek out more ways to monetize them, which litigation funding can help with. He also discussed how life science plaintiffs more regularly sue smaller players than high-tech plaintiffs do, which means defendants will need enough resources to pay damages and settlements.
Learn more here.